擴張型心肌病治療的全球市場-2022-2029

市場概覽

擴張型心肌病治療市場規模預計將在 2021 年達到 4.049 億美元，在預測期間（2022-2029 年）以 5.90% 的複合年增長率增長。

擴張型心肌病 (DCM) 是一種心肌疾病，通常始於心臟的主泵室（左心室）。心室變弱，擴大，無法泵血。心力衰竭的一個常見原因是心臟無法為身體提供足夠的血液，但擴張型心肌病也會導致心律失常、血栓或猝死。擴張型心肌病影響所有年齡段的人，包括嬰兒和兒童，但最常見於 20 至 50 歲的男性。

市場動態

全球擴張型心肌病治療市場的增長受到某些因素的推動，例如心髒病患病率上升、心肌感染人數增加以及藥物和酒精濫用。

在預測期內，心髒病患病率的上升預計將推動全球擴張型心肌病治療市場。

擴張型心肌病每年佔所有充血性心力衰竭病例的 30-40%。擴張型心肌病的估計患病率為 1:2500。這種疾病是心力衰竭最常見的原因之一。屍檢發現的擴張型心肌病的發病率估計為每年每 100,000 人 4.5 例，而臨床發病率為每年每 100,000 人 2.45 例。充血性心髒病的日益流行增加了對有效藥物和治療的緊迫性，從而使擴張型心肌病治療市場受益。

根據世界衛生組織 (WHO) 的 2020 年統計數據，缺血性心髒病佔全球所有死亡人數的 16%。根據 2020 年 2 月在法國發表的題為心力衰竭 (HF) 的文章。根據慢性心力衰竭治療管理和現實生活中心臟失代償的風險，法國約有 100 萬人患有心衰。儘管有完善的治療管理，但仍有大約 70,000 例死亡和超過 150,000 例住院與 HF 相關。

隨著對擴張型心肌病治療的需求不斷增長，幾家大公司已啟動臨床試驗，以開發治療擴張型心肌病的藥物。擴張型心肌病被視為充血性心力衰竭，因為沒有特定的 FDA 批准藥物。

新開發的用於治療擴張型心肌病的藥物包括以下藥物。

ARRY-371797（也稱為 ARRY-797）是 Array 科學家發現的一種口服 p38 絲裂原活化蛋白激□ (MAPK) 抑製劑。一項針對因 Lamin A/C 基因突變導致的擴張型心肌病患者的治療正在進行中的 3 期研究。 2019 年，輝瑞收購了 Array Biopharma 以擴大其管道。它以 PF-07265803 的名稱包含在輝瑞（Pfizer）公司的第 3 階段管道中，用於治療擴張型心肌病患者。

2020 年 2 月，慶應義塾大學的一個研究小組批准了將 iPS 細胞衍生的心肌細胞移植給患有嚴重心力衰竭的患者。目標是在 2020 年內進行研究，目標是擴張型心肌病患者，其中心肌細胞的收縮功能降低。

擴張型心肌病藥物的副作用抑制市場增長

然而，擴張型心肌病藥物對患者造成嚴重不適的副作用限制了市場。此外，可植入設備的可用性和有前途的基因治療是市場的障礙。

行業分析

全球擴張型心肌病治療市場根據波特五力分析、管道分析、監管分析、流行病學和未滿足的需求等各種行業因素對市場進行了深入分析。

細分分析

在預測期間（2022-2029 年），藥物類別部分預計將以最快的複合年增長率增長。

擴張型心肌病治療市場根據藥物類別分為血管緊張素轉換□ (ACE) 抑製劑、β 受體阻滯劑、醛固酮拮抗劑、血管緊張素 II 受體阻滯劑等。由於擴張型心肌病治療對重磅炸彈的需求不斷增加，特別是在發達地區，血管緊張素 II 受體阻滯劑預計將佔據最大的市場份額。

另一方面，醛固酮拮抗劑已被證實與 ARB 或 ACE 抑製劑聯合使用可有效抑制杜氏肌營養不良症 (DMD) 的進展，預計在預測期內將以最高的複合年增長率增長。.這一適應症的批准將進一步加速整體醛固酮拮抗劑的銷售，並對市場增長產生積極影響。一些研究表明，血管緊張素受體阻滯劑如纈沙坦可將住院機會降低 28%。這些藥物還通過降低 37% 的死亡率和減少住院頻率來使收縮性心髒病患者受益。常見的抗心律失常藥物包括胺碘酮、普魯卡因胺和利多卡因。 Corlanor 是一種超極化激活的環核甘酸門控通道阻滯劑，可降低心臟竇房結的自發起搏器活動。美國 FDA 批准 Corlanor（依布雷定）用於治療 6 個月至 18 歲兒童擴張型心肌病引起的穩定症狀性心力衰竭（HF）是竇性心律的症狀性 DCM，NYHA/Ross 分級對 116 名 6 個月至 <18 歲患有 II 至 IV HF 和 □45% 左心室射血力的患者進行的雙盲、安慰劑對照試驗。主要終點是在第一個滴定期後靜息心率較基線降低□20%，而無心動過緩或症狀。

區域分析

北美在全球擴張型心肌病藥物市場中佔有最大的市場份額。

心血管疾病發病率上升、完善的保險政策以及使用先進的醫療保健基礎設施是主要驅動力。在美國，2020 年心衰的總醫療成本（直接和間接）估計為 436 億美元，其中超過 70% 歸因於醫療成本。美國在該地區擁有最大的市場份額。這是由於該國老年人口的增長和心髒病的增加，這推動了該地區的需求。因此，隨著心血管疾病的增加，擴張型心肌病的市場也會增加。

此外，市場參與者正在投資研發以實施新的擴張型心肌病治療藥物。例如，2019 年 7 月，利用人工智能發現藥物的 Recursion Pharmaceuticals 在由 Baillie Gifford 領投的一輪融資中籌集了 1.21 億美元。該公司是一家於 2018 年籌集資金的新藥發現初創公司，該領域的投資者希望通過計算機視覺和機器學習等技術改變成本高昂且費力的藥物發現過程。 Recursion 自己生產罕見病藥物，並尋求與武田、賽諾菲等大型製藥公司合作治療其他罕見病，並希望在腫瘤學和炎症等領域與製藥公司達成交易。我在這裡。

競爭格局

全球擴張型心肌病治療市場由多家主要參與者主導，如 Zensun Shanghai Sci &Tech Co Ltd、Capricor Therapeutics, Inc、AstraZeneca plc、Vericel Corporation、Pfizer Inc、t2cure GmbH、MyoKardia、Kasiak Research Pvt。來自競爭領先公司正在採取多種增長戰略，包括產品發布、收購和合作夥伴關係，為全球擴張型心肌病治療市場的增長做出貢獻。例如，2019 年 10 月，諾華公司在美國食品藥品監督管理局 (FDA) 批准了 Entresto (sacubitril/valsartan)，用於治療患有全身性左心室收縮功能障礙 (HF) 的症狀性心力衰竭 (HF) 1 年的兒科患者。年齡及以上。（FDA）批准。 Entresto 有望降低 NT-proBNP 並改善心血管預後。

值得關注的重點公司

輝瑞公司

概述輝瑞公司是一家美國跨國製藥公司，在癌症、炎症、心血管和其他治療領域提供藥物、疫苗、醫療設備和消費者保健產品。輝瑞日本公司在 15 個治療領域擁有 150 多種產品組合。該公司為廣泛的醫學領域開發和製造藥物和疫苗，包括免疫學、腫瘤學、心髒病學、內分泌學和神經學。

產品組合 Camdios 是第一個可用於心肌病患者的新型治療選擇。

重大進展。 2022 年 8 月，輝瑞停止了擴張型心肌病治療藥物 Emprumapimod 的開發。

全球擴張型心肌病治療市場報告提供了大約 40 多個市場數據表、45 多個圖表和 180 頁的結構。

內容

第1章研究方法與範圍

• 調查方法
• 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

• 按藥物類別劃分的市場細分
• 按分銷渠道劃分的市場細分
• 按地區劃分的市場細分

第 4 章市場動態

• 市場影響因素
• 驅動程序
  • 心髒病增加
  • 吸毒和酗酒增加
• 限制因素
  • 擴張型心肌病藥物的副作用
• 商機
• 影響分析

第5章行業分析

• 波特五力分析
• 流行病學
• 管道分析
• 監管分析
• 未滿足的需求

第 6 章按藥物類別

• 血管緊張素轉換□ (ACE) 抑製劑
• β-受體阻滯劑
• 醛固酮拮抗劑
• 血管緊張素 II 受體阻滯劑
• 其他

第 7 章按銷售渠道

• 醫院和診所
• 在線頻道
• 其他

第 8 章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第 9 章競爭格局

• 競爭場景
• 市場情況/份額分析
• 併購分析

第 10 章公司簡介

• 阿斯利康公司
  • 公司概況
  • 產品組合和描述
  • 主要亮點
  • 財務摘要
• Zensun Shanghai Sci & Tech Co Ltd
• Pfizer Inc.
• Capricor Therapeutics, Inc.
• MyoKardia
• Kasiak Research Pvt. Ltd.
• Array BioPharma
• Vericel Corporation
• t2cure GmbH（*List is not exhaustive）

第11章 DataM

Market Overview

Dilated Cardiomyopathy Therapeutics Market size was valued at US$ 404.9 million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.90% during the forecast period (2022-2029).

Dilated cardiomyopathy (DCM) is an abnormality of the heart muscle, usually starting in your heart's main pumping chamber (left ventricle). The ventricle becomes weakened and enlarged and can't pump blood. A common cause of heart failure is the heart's inability to supply the body with enough blood, and dilated cardiomyopathy also contributes to irregular heartbeats (arrhythmias), blood clots, or sudden death. People of all ages are affected by DCM, including infants and children, but it is most common in men ages 20 to 50.

Market Dynamics

The global dilated cardiomyopathy therapeutics market growth driven by certain factors such by rising prevalence of heart problems, the increasing number of people suffering from cardiac muscle infections, and drug or alcohol abuse.

Rising prevalence of heart problems, is expected to drive the global dilated cardiomyopathy therapeutics market during the forecast period

Dilated cardiomyopathy accounts for 30-40% of the total number of congestive heart failures each year. The estimated prevalence of dilated cardiomyopathy is 1:2500. This condition is one of the most common causes of heart failure. The incidence of dilated cardiomyopathy discovered at autopsy is estimated to be 4.5 cases per 100,000 population per year, whereas the clinical incidence is 2.45 cases per 100,000 population per year. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.

According to statistics from the World Health Organization (WHO) for 2020, ischemic heart disease is to blame for 16% of all fatalities worldwide. According to a February 2020 article titled "Heart failure (HF) in France: Chronic Heart Failure Therapeutic Management and Risk of Cardiac Decompensation in Real-Life Setting," approximately one million people in France would be affected by HF. Despite well-defined treatment management, there are nearly 70,000 HF-related deaths and more than 150,000 hospitalizations.

With the rising demand for dilated cardiomyopathy treatment, several major companies have initiated to carry out clinical trials to develop drugs for dilated cardiomyopathy. There is no specific FDA-approved drug for dilated cardiomyopathy because of which the treatment administered is the same as that for congestive heart failure.

Some of the emerging drugs for the treatment of dilated cardiomyopathy are:

ARRY-371797, also known as ARRY-797, is an oral, p38 mitogen-activated protein kinase (MAPK) inhibitor discovered by Array scientists. It is under phase III trial to treat patients suffering from dilated cardiomyopathy because of a Lamin A/C gene mutation. In 2019, Pfizer acquired Array Biopharma to expand its pipeline. This drug is in phase III pipeline drugs of Pfizer under the name PF-07265803 for the treatment of patients affected by dilated cardiomyopathy.

In February 2020, a Keio University research team was given the green light to transplant heart muscle cells derived from iPS cells into patients who have experienced severe heart failure. The study aims to conduct study by the end of 2020 and targets patients with dilated cardiomyopathy, which lowers the systolic function of heart muscle cells.

Side effects associated with dilated cardiomyopathy therapeutics hampering the growth of the market

However, the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market. Moreover, the availability of implantable devices and promising gene therapy are acting as roadblocks to the market.

Industry Analysis

The global dilated cardiomyopathy therapeutics market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, pipeline analysis, regulatory analysis, regulatory analysis, epidemiology, unmet needs etc.

Segment Analysis

The drug class segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Based on drug class, the dilated cardiomyopathy therapeutics market is segmented by drug class into angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, angiotensin II receptor blockers, and others. The angiotensin II receptor blockers drug class is estimated to account for the largest market share, owing to the rising demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions.

On the other hand, the aldosterone antagonists are expected to grow at the highest CAGR over the forecast period due to the identified positive impact of aldosterone antagonists when used in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne muscular dystrophy (DMD). Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which would positively impact market growth. According to some studies, the angiotensin receptor blockers such as valsartan can reduce the probability of hospitalization by 28%. These drugs are also effective for patients with systolic heart disease by reducing deaths by 37% and reducing hospitalization frequency. Common anti-arrhythmia medications include amiodarone, procainamide, and lidocaine. Corlanor is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the cardiac sinus node's spontaneous pacemaker activity. The US FDA approval of Corlanor (ivabradine) for the treatment of stable symptomatic heart failure (HF) due to dilated cardiomyopathy in pediatric patients aged 6 months to 18 years was based on a randomized, double-blind, placebo-controlled trial in 116 patients aged 6 months to less than 18 years with symptomatic DCM in sinus rhythm, NYHA/Ross class II to IV HF, and left ventricular ejection fraction ≤45%. The study's primary endpoint was ≥ a 20% reduction in resting heart rate from baseline without bradycardia or symptoms after an initial titration period.

Geographical Analysis

North America region holds the largest market share of the global dilated cardiomyopathy therapeutics market

The rising incidence of cardiovascular diseases, well-established insurance policies, and the availability of advanced healthcare infrastructure are the major factors. In the USA, the total cost of care (direct and indirect costs) for HF in 2020 is estimated at $43.6 billion, with over 70% of costs attributed to medical costs. In this region, the United States holds the largest market share due to rising geriatric populations, an increasing number of heart diseases in the country, which boosts the demand in this region. Hence, as the number of cardiovascular diseases increases, the market for dilated cardiomyopathy also increases.

Besides, the market players are investing in research and development to conduct new treatment drugs for dilated cardiomyopathy. For instance, in July 2019, Recursion Pharmaceuticals, which uses artificial intelligence to discover drugs, has raised $121 million in a round led by Baillie Gifford. The company is a new drug discovery start-up to raise funds in 2018, as investors flock to the sector hoping that the costly and cumbersome process of finding a drug will be transformed by techniques such as computer vision and machine learning. Recursion is trying to make its own drugs for rare diseases and partner with major pharmaceutical companies such as Takeda and Sanofi on other rare diseases, and hoping to sign deals with pharma companies in areas such as oncology and inflammation.

Competitive Landscape

The global dilated cardiomyopathy therapeutics market is moderately competitive with several major players, including Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer Inc., t2cure GmbH, MyoKardia, Kasiak Research Pvt. Ltd., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the dilated cardiomyopathy therapeutics market globally. For instance, in October 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for Entresto (sacubitril/valsartan) for the treatment of symptomatic heart failure (HF) with systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older. Entresto reduces NT-proBNP and is expected to improve cardiovascular outcomes.

Key Companies to Watch

Pfizer Inc

Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio: Camzyos is the first novel therapy option available for cardiomyopathy patients.

Key Developments: In August, 18th 2022, Pfizer discontinued the development of dilated cardiomyopathy drug emprumapimod.

The global dilated cardiomyopathy therapeutics market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Drug class
• 3.2. Market Snippet by Distribution Channel
• 3.3. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
• 4.2. Drivers
  • 4.2.1. Rising prevalence of heart diseases
  • 4.2.2. Increasing drugs and alcohol abuse
  • 4.2.3. XX
• 4.3. Restraints:
  • 4.3.1. Side-effects of dilated cardiomyopathy drugs
  • 4.3.2. XX
• 4.4. Opportunity
• 4.5. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology
• 5.3. Pipeline analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. By Drug class

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment.
• 6.3. Market Attractiveness Index, By Drug Class Segment
  • 6.3.1. Angiotensin-converting enzyme (ACE) Inhibitors*
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.3.2. Beta-blockers
  • 6.3.3. Aldosterone antagonists
  • 6.3.4. Angiotensin II Receptor Blockers
  • 6.3.5. Others

7. By Distribution Channel

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
• 7.3. Market Attractiveness Index, By Distribution Channel Segment
  • 7.3.1. Hospitals & Clinics*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Online Channels
  • 7.3.3. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. The U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. The U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Italy
    • 8.3.5.5. Spain
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. Australia
    • 8.5.5.5. Rest of Asia Pacific
• 8.6. The Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. AstraZeneca plc*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Key Highlights
  • 10.1.4. Financial Overview
• 10.2. Zensun Shanghai Sci & Tech Co Ltd
• 10.3. Pfizer Inc.
• 10.4. Capricor Therapeutics, Inc.
• 10.5. MyoKardia
• 10.6. Kasiak Research Pvt. Ltd.
• 10.7. Array BioPharma
• 10.8. Vericel Corporation
• 10.9. t2cure GmbH (*List is not exhaustive)

11. DataM Intelligence

• 11.1. Appendix
• 11.2. About Us and Services
• 11.3. Contact Us